These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30944821)

  • 21. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol.
    Rahman K; Desai C; Iyer SS; Thorn NE; Kumar P; Liu Y; Smith T; Neish AS; Li H; Tan S; Wu P; Liu X; Yu Y; Farris AB; Nusrat A; Parkos CA; Anania FA
    Gastroenterology; 2016 Oct; 151(4):733-746.e12. PubMed ID: 27342212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD.
    Jiang X; Zheng J; Zhang S; Wang B; Wu C; Guo X
    Front Med (Lausanne); 2020; 7():361. PubMed ID: 32850884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics.
    He X; Ji G; Jia W; Li H
    Int J Mol Sci; 2016 Mar; 17(3):300. PubMed ID: 26999104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
    Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
    Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SIRT3 Deficiency Promotes High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis.
    Chen M; Hui S; Lang H; Zhou M; Zhang Y; Kang C; Zeng X; Zhang Q; Yi L; Mi M
    Mol Nutr Food Res; 2019 Feb; 63(4):e1800612. PubMed ID: 30525304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gut Microbiota and Host Reaction in Liver Diseases.
    Fukui H
    Microorganisms; 2015 Oct; 3(4):759-91. PubMed ID: 27682116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY; Yang M; Edwards S; Ye SQ
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Da-Chai-Hu Decoction Ameliorates High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Through Remodeling the Gut Microbiota and Modulating the Serum Metabolism.
    Cui H; Li Y; Wang Y; Jin L; Yang L; Wang L; Liao J; Wang H; Peng Y; Zhang Z; Wang H; Liu X
    Front Pharmacol; 2020; 11():584090. PubMed ID: 33328987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
    Chu H; Williams B; Schnabl B
    Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
    de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB
    Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intestinal microbiota and nonalcoholic steatohepatitis.
    Brandl K; Schnabl B
    Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of gut microbial metabolites in nonalcoholic fatty liver disease.
    Zhao ZH; Lai JK; Qiao L; Fan JG
    J Dig Dis; 2019 Apr; 20(4):181-188. PubMed ID: 30706694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites.
    Ding Y; Yanagi K; Cheng C; Alaniz RC; Lee K; Jayaraman A
    Pharmacol Res; 2019 Mar; 141():521-529. PubMed ID: 30660825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
    Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
    Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between Changes in Microbiota and Liver Steatosis Induced by High-Fat Feeding-A Review of Rodent Models.
    Gómez-Zorita S; Aguirre L; Milton-Laskibar I; Fernández-Quintela A; Trepiana J; Kajarabille N; Mosqueda-Solís A; González M; Portillo MP
    Nutrients; 2019 Sep; 11(9):. PubMed ID: 31505802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
    Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
    Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.